Corporate Banner
Satellite Banner
Proteomics
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

A Gene Conserved from Worms to Humans Opens the Door to new Therapeutics

Published: Friday, June 21, 2013
Last Updated: Friday, June 21, 2013
Bookmark and Share
Gene shows promising therapeutic strategies in cancer and in some types of blindness.

Researchers from the Bellvitge Biomedical Research Institute (IDIBELL), led by Julian Cerón, have demonstrated the dual function of a protein, RSR-2, both in the DNA transcription machinery as in the RNA maturation complex (splicing) in the worm C. elegans. It is the first time that this dual function of a protein in a living multicellular organism has been confirmed.

RSR-2 protein is conserved from yeast to humans. The results of the study are published in the journal PLoS Genetics.

Gene Transcription and splicing

DNA encoding proteins passes through several stages to synthesize them. In this process there are two machineries: the transcription complex in which DNA passes to RNA and the RNA processing complex (splicing) which involves the removal of sequence fragments called introns.

As IDIBELL researcher Julian Cerón explains, "it has been shown in cell lines and in vitro that proteins from the two machineries interact physically, and that proteins of the transcription machinery are present in the splicing machinery and vice-versa. However, the functional interaction in both machineries had not been studied before in a living multicellular organism".

Researchers generated transgenic animals and an antibody against the protein RSR-2 in order to observe where was the protein and they saw that "as we expected, it was interacting with DNA sequences with introns and therefore involved in splicing, but also we observed that the protein was associated with genes without introns and therefore also involved in the process of gene transcription", explains Cerón.

Interaction with retinoblastoma pathway

In previous research, Julian Cerón, had identified a genetic interaction between the RSR-2 gene with the retinoblastoma pathway a genetic pathway deregulated in most human tumors, "but as RSR-2 belonged to the splicing machinery and retinoblastoma participates in the remodelling of chromatin in the transcription machinery, we did not know how to interpret this interaction".

Proving that RSR-2 also works in DNA transcription Ceron implies that "we have found the missing piece of the puzzle. If retinoblastoma and RSR-2 need each other to work, it opens the door to changing RSR-2 as a novel therapeutic strategy against cancer".

Target for Retinitis Pigmentosa

RSR-2 protein could also be a new therapeutic target in human blindness for a specific type of retinitis pigmentosa. PRP8 mutations present in the splicing machinery cause a type of progressive blindness known as retinitis pigmentosa. Cerón team has shown that the RSR-2, like its counterparts in yeast and humans, interacts with the gene PRP8 opening the door to new therapies through the modification of RSR-2.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,300+ scientific posters on ePosters
  • More than 4,900+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

High Levels of RANK Protein Interferes with the Differentiation of Mammary Cells
Levels of this protein increase with age, which could explain the increase in breast cancer risk associated with age.
Wednesday, September 11, 2013
Identified a Key Protein in Maintaining the Identity of B Lymphocytes
This finding could be useful for the study of blood diseases such as lymphoma and leukemia.
Monday, June 10, 2013
Ángel Carracedo: ''Only 50% of First-Line Drugs are Effective''
The Professor of Legal Medicine and director of the Genomic Medicine lab at the University of Santiago de Compostela, talked of the future challenges of the field of pharmacogenetics in the clinic.
Wednesday, March 20, 2013
Scientific News
Liquid Biopsies: Miracle Diagnostic or Next New Fad?
Thanks to the development of highly specific gene-amplification and sequencing technologies liquid biopsies access more biomarkers relevant to more cancers than ever before.
Detecting Alzheimer's with Smell Test
Odour identification test may offer low-cost alternative for predicting cognitive decline and detecting early-stage Alzheimer’s disease.
Uncovering Rhinovirus C Structure
Researchers have determined the structure of rhinovirus C. Their findings may aid the development of antiviral therapies and vaccines.
New Centre Offers Ultra-Speed Protein Analysis
UW-Madison researchers to establish development centre for next-gen protein measurement technologies.
Protein Nanocages Could Improve Drug Design and Delivery
HHMI scientists have designed and built 10 large protein icosahedra that are similar to viral capsids that carry viral DNA.
Virus Inspired Cell Cargo Ships
Virus-inspired container design may lead to cell cargo ships following construction of ten large, two-component, icosahedral protein complexes.
Protein Reinforces Growth of Damaged Muscles
Biologists have found a protein involved in stem cells that bolsters damaged muscle tissue growth - potential for muscle degeneration treatments.
Structure of Cold Virus Solved
Researchers have identified the structure of an elusive cold virus linked to child asthma and respiratory infections, providing the foundation for treating the virus.
New Protein Model Could Accelerate Drug Development
Stony Brook-led international research team creates ultra-fast approach to model protein interactions.
Researchers Can Control Genes Involved in Cancer
A new way to control the activity of a protein, that is often upregulated in cancer, has been discovered by Moffitt researchers through monoubiquitination mechanism.
Scroll Up
Scroll Down
SELECTBIO

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,300+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,900+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!